英夫利昔单抗治疗克罗恩病坏疽性脓皮病。
文章的细节
-
引用
复制到剪贴板 -
张建军，刘建军，刘建军，等
英夫利昔单抗治疗克罗恩病坏疽性脓皮病。
中国生物医学工程学报，2004;49(9):1454-7。
- PubMed ID
-
15481318 (PubMed视图］
- 摘要
-
坏疽性脓皮病(PG)是一种溃疡性非传染性皮肤疾病，见于1 - 5%的炎症性肠病患者。PG的发病机制尚未确定，但可能与异常T细胞反应和tnf - α的产生有关，tnf - α是一种强效的促炎细胞因子。英夫利昔单抗是一种针对tnf - α的嵌合单克隆抗体，已被批准用于治疗克罗恩病。我们报告了4例用英夫利昔单抗治疗克罗恩病的PG患者，其中PG完全愈合。对4例活动性瘘管性克罗恩病合并PG患者进行了治疗。患者均为女性，年龄48 ~ 60岁，平均年龄54岁。4例患者中有3例PG病变位于下肢;1例患者有肠周病变。所有患者至少都有结肠的克罗恩病。患者接受单次输注或连续三次输注5 mg/kg英夫利昔单抗。 All four patients demonstrated rapid healing of PG within 4 weeks of the first infusion of Infliximab. PG healing followed improvement in bowel disease. Complete resolution without recurrence was noted in all patients. Rapid resolution of PG was noted in four female patients with fistulizing Crohn's disease treated with Infliximab. Healing was complete, without recurrence. The anti-TNF-alpha properties of Infliximab suggest that healing may be mediated by the drug's effect on cytokine pathways, perhaps by blunted T cell activation early in the inflammatory cascade. We suggest an independent effect of Infliximab on PG.